<DOC>
	<DOCNO>NCT02498925</DOCNO>
	<brief_summary>The prevalence major depressive disorder ( MDD ) relatively low childhood ( i.e. , 1-3 % ) , increase substantially adolescence . By age 18 , approximately 15 % adolescent experience least one episode MDD . A grow body research implicate abnormality reward circuitry play critical role development maintenance depressive symptom adolescent . Importantly , reward-circuitry abnormality link anhedonia ( i.e. , decreased pleasure blunt reactivity reward stimulus ) . Behavioral Activation ( BA ) represent promise - relatively simple deliver - nonpharmacologic intervention adolescent depression , show least effective Cognitive Behavioral Therapy ( CBT ) regard symptom reduction lower risk relapse adult sample . More recently , promise data emerge application BA depress adolescent . BA conceptualize treatment directly target anhedonia . More specifically , BA target anhedonia behavioral change strategy aim gradually increase patient ' exposure engagement reward stimulus positively reinforce experience . Given treatment focus , BA may particularly beneficial adolescent struggle relatively elevated level anhedonic symptom . Accordingly , present study examine role anhedonia reward function predict treatment response BA . In addition , analysis conduct examine reward-related neural behavioral mechanism underlie anhedonic symptom improvement BA .</brief_summary>
	<brief_title>Examining Reward-Related Predictors Mechanisms Change BA Treatment Anhedonic Adolescents</brief_title>
	<detailed_description>Participants research include 35 anhedonic adolescent 36 demographically match healthy participant recruit great Boston community Dr. Webb McLean Hospital 's Center Depression , Anxiety Stress Research . The anhedonic adolescent undergo 12 week Behavioral Activation therapy . This study include three session : - The first session involve diagnostic interview , series questionnaire assessment . - The second session take place McLean Hospital 's Neuroimaging Center , involve fMRI brain scan administration two behavioral task , well questionnaire . - Following 12-weeks treatment , anhedonic adolescent return McLean Hospital 's Neuroimaging Center fMRI brain scan , two behavioral task , questionnaire . The healthy control group complete three assessment correspond time point .</detailed_description>
	<mesh_term>Anhedonia</mesh_term>
	<criteria>General Both gender , ethnicity Ages 1318 English first language English fluency Right hand Smartphone iOS Android platform ( EMA ) Anhedonic Sample : Total Snaith Hamilton Pleasure Scale ( SHAPS ) score â‰¥ 3 ; Healthy Control Sample : Total SHAPS score = 0 General History head trauma loss consciousness History seizure disorder Serious unstable medical illness , include cardiovascular , hepatic , renal , respiratory , endocrine , neurologic hematologic disease History cocaine stimulant use ( e.g. , amphetamine , cocaine , methamphetamine ) History use dopaminergic drug ( include methylphenidate ) Clinical laboratory evidence hypothyroidism Systemic medical neurological illness could impact fMRI measure cerebral blood flow Meet standard exclusion criterion fMRI scan ( e.g . claustrophobia , cardiac pacemaker , neural pacemaker , surgically implant metal device , cochlear implant , metal brace , metal object body ) ; Positive urine pregnancy test A. Anhedonic Adolescents : Additional Subjects suicidal ideation outpatient BA treatment determine unsafe inappropriate study clinician . These patient immediately refer appropriate clinical treatment History current diagnosis follow DSM5 psychiatric illness : schizophrenia spectrum psychotic disorder , bipolar disorder , OCD , PTSD , substance ( include alcohol ) use disorder within past 12 month lifetime severe substance use disorder ( i.e. , meet former DSMIV criterion past substance dependence ) . Simple phobia , social anxiety disorder , panic disorder , generalize anxiety disorder allow secondary anhedonia Meet criterion chronic depression ( current episode &gt; 2 year ) Currently receive psychotropic treatment psychotherapy Absence psychotropic medication : 8 week fluoxetine , 4 week neuroleptic , 8 week benzodiazepine , 6 week antidepressant B . Healthy Control Adolescents : Additional Elevated depressive symptom assess phone screen History meeting criterion DSM5 psychiatric substancerelated disorder Use psychiatric medication Family history ( firstdegree relative ) psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>